

# Market Announcement

25 June 2025

---

## Percheron Therapeutics Limited (ASX: PER) – Trading Halt

Trading in the securities of Percheron Therapeutics Limited ('PER') will be halted at the request of PER, pending the release of an announcement by PER.

Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of:

- the commencement of normal trading on Friday, 27 June 2025; or
- the release of the announcement to the market.

PER's request for a trading halt is attached below for the information of the market.

### Issued by

ASX Compliance

25 June 2025

Ms Melissa Kostopoulos  
Adviser, Listings Compliance  
ASX Compliance Pty Ltd  
Level 4, North Tower,  
Rialto Building  
525 Collins Street  
Melbourne VIC 3000

Via email: [tradinghaltsmelbourne@asx.com.au](mailto:tradinghaltsmelbourne@asx.com.au)

Dear Melissa,

**Percheron Therapeutics Limited – Trading Halt Request**

In accordance with ASX Listing Rule 17.1, Percheron Therapeutics Limited (ASX:PER) (the **Company**) requests an immediate trading halt in respect of the Company's securities prior to the commencement of trading on Wednesday, 25 June 2025, pending an announcement in relation to a licensing transaction.

In accordance with ASX Listing Rule 17.1, the Company provides the following information:

- a) the Company is seeking the trading halt pending an announcement in relation to a licensing transaction;
- b) the Company requests that the trading halt last until the earlier of the Company releasing an announcement in relation to a licensing transaction and the commencement of trading on Friday, 27 June 2025;
- c) the Company anticipates that the trading halt will cease on it making the announcement in relation to a licensing transaction;
- d) the Company is not aware of any reason why the trading halt should not be granted; and
- e) the Company is not aware of any further information which needs to be disclosed to the market at the time of seeking the trading halt.

Please do not hesitate to contact me if you require any further information.

Your sincerely,

Deborah Ambrosini  
Company Secretary  
Percheron Therapeutics Limited